Damora Therapeutics (DMRA) Total Non-Current Liabilities (2024 - 2026)

Damora Therapeutics has reported Total Non-Current Liabilities for 3 years, with the latest figure at $18.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 1070.39% year-over-year to $18.9 million; the trailing twelve-month figure through Mar 2026 stood at $18.9 million (up 1070.39% YoY), and the FY2025 full-year result was $20.1 million, up 1495.07% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $18.9 million, down from $20.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $20.1 million in Q4 2025, with the low at $1.3 million in Q4 2024.
• Historically, Total Non-Current Liabilities has averaged $7.9 million across 3 years, with a median of $2.7 million in 2025.
• Annual changes were most pronounced in 2025 — Total Non-Current Liabilities jumped 1495.07% — and 2026, when it soared 1070.39%.
• Damora Therapeutics' Total Non-Current Liabilities stood at $1.3 million in 2024, then jumped by 1495.07% to $20.1 million in 2025, then decreased by 6.04% to $18.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $18.9 million (Q1 2026), $20.1 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.